tbuckley/cabot-search huggingface dataset:
AB1122-HPR Locus of Control and The Phenomenon of Alexithymia in Ankylosing Spondylitis Patients
Authors: M. Ramkhelawon, G. Suleymanova, R. Grekhoff, E.G. Cherkesova
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> To examine the role of locus of control and the phenomenon of alexithymia in the formation of psychosomatic personality traits in ankylosing spondylitis (AS) patients. <h3>Methods</h3> The group studied, comprised of 27 patients suffering from AS. The selection of patients for the study was conducted in accordance with the recommendations of the group of experts working on AS (ASAS, 2003). The patients were of an average age - 44, 94±13, 8 years and had an average duration of the disease - 3, 02 ± 3, 69 years. The main contingent of patients with AS was represented by males (89%). A study of locus of control was conducted by the method of “level of subjective control” (Bazhin E. F., et al. 1987). The study of alexithymia was conducted using the Toronto Alexithymia Scale (TAS) (G. J. Taylor et al., 1985). <h3>Results</h3> The study of locus of control in patients with AS showed a significant trend towards external locus of control in common sphere (3,81+1,387), as well as on the scale of failures (3,51+0,64), family relations (4,18+0,55), professional relations (2,74+0.98) and in relation to health (4,66+1,94). Trends towards internal locus of control were observed in the sphere of interpersonal interaction and achievements (5, 14+0, 71 and 5.0+1, 24 respectively). Correlation between the levels of locus of control with other clinical and psychological characteristics, such as age, activity, duration of disease and the level of neurotic disorders in patients has not been established. A high level of alexithymia (77, 35±1.8 points) was also recorded in patients with AS. The level of alexithymia as such, did not depend on sex, age, character of duration and activity of the pathological process, but was inversely correlated with the level of education of the patients (r=-0.37 with p=0,028) and internality in relation to the disease (r=-0,64, p=0.031). <h3>Conclusions</h3> Thus, a certain correlation is formed between the development of the alexithymia phenomenon and some clinical and psychological characteristics in AS patients. This correlation is usually causal in nature, the understanding of which has implications for the organization of preventive measures, aimed at correction of alexithymia traits. Characteristics of locus of control in patients with AS can largely be predetermined by the peculiarities in the formation of personal relationships and the choice of certain strategies. These changes may hinder the effectiveness of therapeutic interventions and need for psychological adjustment in time. <h3>Disclosure of Interest</h3> None declared
AB0990 Rituximab in Chronic Autoimmune Rheumatic Diseases: Safety and Clinical Profile after 12 and 24 Months of Follow-Up
Authors: C. Mata Martínez, L. Garcia-Montoya, J.G. Ovalles-Bonilla, J.C. Nieto, F.J. Lόpez-Longo, L. Valor, B. Serrano, R.D. González, C.N. Saenz, M. Correyero, I. Janta, J. Martínez Barrio, E. Naredo, C. González, D. Hernandez, I. Monteagudo
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rituximab (RTX) is a chimeric monoclonal anti-CD20 antibody. Several studies have proved its safety when used in different autoimmune chronic rheumatic diseases (ACRD). However, the real conditions of daily practice are not comparable to the ideal frame of a clinical trial. <h3>Objectives</h3> The aim of this study is to describe the profile of safety of RTX in patients with ACRD 12 and 24 months after the administration of the first cycle. <h3>Methods</h3> It is an observational retrospective study of patients diagnosed with ACRD who received treatment with RTX. Data were collected on demographic, clinical and biochemical profiles right before the first infusion, 12 and 24 months later. Other parameters were concomitant medication, prednisone dose, previous biologic treatment, accumulated RTX dose, infusion and anaphylactic reactions, infections, tumor relapses.Comparison was done using Wilcoxon non parametric test. <h3>Results</h3> Data were collected from 50 patients that received RTX. 24 months after treatment no major cytopenias or hypogammaglobulinemia were found. Hepatic and lipid profile did not show any alterations and complement levels did not experiment relevant changes. The average dose of prednisone was reduced significantly 1 year after the treatment. A decline in levels of acute phase reactants and antibodies was observed. This effect was maintained in every parameter with the exception of the rheumatoid factor; which continued presenting a downwards trend after 24 months. Concerning the infections, 3 patients were hospitalised (because of severe infections): two of them suffered from pneumonia and the other one required a surgical intervention in order to replace an infected prosthetic knee. 14 mild infections were registered: 8 mucocutaneous, 2 gastrointestinal, 2 respiratory and 2 genitourinary. There were no cases of primoinfection, reactivation of hepatic viruses or mycobacteria. No tumoral relapses, new diagnosis of tumors or demyelinising diseases were observed. 5 patients experimented mild infusion reactions but none of them had an anaphylactic reaction or died. <h3>Conclusions</h3> RTX has reduced the average maintenance dose of prednisone and also lowered the levels of serum immunoglobulins (including antibodies) without inducing hypogammaglobulinemia. It has proved to be a relatively safe treatment that does not cause hematic, hepatic toxicity or deep immunosuppresion after 12 and 24 months of follow up in patients with ACRD. Further studies are needed in order to evaluate long term safety of RTX. <h3>References</h3> Becerra E et al; Long-term Safety of Rituximab in Patients With Rheumatoid Arthritis. Int J Clin Rheumatol. 2012;7(4):383–390. <h3>Disclosure of Interest</h3> None declared
Inhibition of Related JAK/STAT Pathways with Molecular Targeted Drugs Shows Strong Synergy with Ruxolitinib in Chronic Myeloproliferative Neoplasms
Authors: Santiago Barrio, Miguel Gallardo, Alicia Arenas, Rosa M. Ayala, Inmaculada Rapado, Daniel Rueda, Ana Jimenez, Enriqueta Albizua, Carmen Burgaleta, Florinda Gilsanz, Joaquin Martinez
Journal: Blood (2012)
Effect of the Terminal Complement Inhibitor Eculizumab on Patient Reported Outcomes in Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase III Triumph Study Results.
Authors: Robert A. Brodsky, Petra Muus, Ulrich Dührsen, Anita Hill, Monica Bessler, Steven Coutre, Raquel De Paz, Tibor Moskovits, Ryotaro Nakamura, Eric Van den Neste, Alberto Zanella, Kerry Quinn-Senger, Henk-Andre Kroon, David Cella
Journal: Blood (2006)
SAT0209 Idiopathic Inflammatory Myopathies: Evaluation of Skeletal Muscle Glucose Metabolism by PET-CT 18F-FDG
Authors: J. Matuszak, A. Meyer, I.-J. Namer, B. Geny, J. Sibilia, C. Blondet
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> There is a need for tools to measure muscle disease activity in inflammatory myopathies (IM). <h3>Objectives</h3> To assess the contribution of metabolic imaging with positron emission tomography combined with computed tomography (PET-CT) 18F fluorodeoxyglucose-(18F-FDG) for muscle disease activity assessment in patients with IM. <h3>Methods</h3> The SMGM was higher in IM than in the control group in visual analysis (p&lt;0.001) and quantitative analysis (p&lt;0.001). No correlation was found between the SMGM and the muscle histological findings. In addition, the quantitative measurement of SMGM was significantly correlated with serum CK levels (Spearman ρ=0.47, p&lt;0.01) and with the MITAX (Spearman ρ=0.72; p=0.001). Finally, in 9 patients who underwent two consecutive 18F-FDG PET-CT, the evolution of the SMGM was concordant with the clinical course according to the MITAX in 8. <h3>Results</h3> The SMGM was higher in IM than in the control group in visual analysis (p&lt;0.001) and quantitative analysis (p&lt;0.001). No correlation was found between the SMGM and the muscle histological findings. In addition, the quantitative measurement of SMGM was significantly correlated with serum CK levels (Spearman ρ=0.47, p&lt;0.01) and with the MITAX (Spearman ρ=0.72; p=0.001). Finally, in 9 patients who underwent two consecutive 18F-FDG PET-CT, the evolution of the SMGM was concordant with the clinical course according to the MITAX in 8. <h3>Conclusions</h3> These data suggested that 18F-FDG PET-CT, which is useful for the screening of cancer associated IM, is also helpful for the measurement of IM muscle disease activity. <h3>Disclosure of Interest</h3> None declared
Clinical Response to Idasanutlin (RG7388) in Acute Myeloid Leukemia Patients Is Associated with Pre-Treatment MDM2 Protein Expression in Leukemic Blasts and Leukemic Stem Cells
Authors: Bernhard Reis, Lori Jukofsky, Gong Chen, Giovanni Martinelli, Hua Zhong, Venus So, Michael J. Dickinson, Mark W. Drummond, Sarit E. Assouline, Maneja Hashemyan, Michel Theron, Steven Blotner, Je-Hwan Lee, Margaret Kasner, Sung-Soo Yoon, Ruediger Rueger, Karen Seiter, Steven Middleton, Kevin R. Kelly, Norbert Vey, Karen W.L. Yee, Gwen Nichols, Lin-Chi Chen, William E. Pierceall
Journal: Blood (2015)
Prognostic Significance of Multidrug Resistance Gene 1 (MDR1), Multidrug Resistance-Related Protein (MRP) and Lung Resistance Protein (LRP) mRNA Expression in Acute Leukemia.
Authors: Hee Jin Huh, Chan-Jeoung Park, Seongsoo Jang, Eul-Ju Seo, Hyun-Sook Chi, Je-Hwan Lee, Kyoo-Hyung Lee, Jong Jin Seo, Hyung Nam Moon, Thad Ghim
Journal: Blood (2005)
Kinesin Family Member 20A (KIF20A) Is Specifically down Regulated in 5q- CD34+ and CD61+ Cells and Uniparental Disomy Is Not a Feature of 5q- Syndrome.
Authors: Nicholas C. Lea, Azim Mohamedali, Natalie Twine, Joop Gaken, Nigel Westwood, Wendy Ingram, Ghulam Mufti
Journal: Blood (2006)
PTH-095 The Northern Ireland Experience of Selective Internal Radiation Therapy: Abstract PTH-095 Table 1
Authors: BV Layard, A McNeice, PT Kennedy, WJ Cash, NI McDougall
Journal: Gut (2016)

<h3>Introduction</h3> Selective Internal Radiation Therapy (SIRT) is liver-directed therapy for the treatment of non-resectable primary or secondary liver tumours. Radioactive microspheres containing yttrium-90 are delivered into the arterial blood supply of the liver, where they become lodged in vessels within the tumour, allowing targeted radiation therapy to occur. Currently this innovative treatment concept is recommended when established treatment regimens have failed. <h3>Methods</h3> SIRT is performed at a single regional centre in Northern Ireland. All potential candidates are discussed at a regional hepatobiliary multi-disciplinary meeting and all have appropriate work-up for SIRT performed to exclude shunting. Each patient receives sensitising chemotherapy in the days prior to SIRT unless contraindicated. We reviewed all SIRT treatments, looking at indications, complications and outcomes between September 2010 and September 2015. <h3>Results</h3> 27 patients underwent SIRT. The mean age was 62 years old (range 41–77). The indications were liver metastases secondary to colorectal cancer (63%), hepatocellular carcinoma (30%), and liver metastases secondary to neuroendocrine tumours (7%). Each patient had a follow up single-photon emission computed tomography (SPECT) scan within 24 hours, none of which demonstrated any significant extra-hepatic activity. 6 patients remain alive at the time of writing with a time range of between 6 and 28.6 months post-SIRT. Of the remaining 21 patients, the median survival was 9.2 months (ranging from 25 days to 59.4 months). Complications Two patients died within 30 days. One, aged 72, with liver metastases from colorectal cancer died from progression of liver metastases with jaundice and ascites. The other, aged 77, with hepatocellular carcinoma died from multi-organ failure. One patient, treated for hepatocellular carcinoma with underlying Childs-Pugh B cirrhosis died 39 days following SIRT with decompensation of his liver disease. <h3>Conclusion</h3> Survival in the 3 patient groups treated by SIRT at our centre showed wide variation. In particular, those receiving SIRT for HCC following prior TACE therapy had the poorest survival. The optimal indications for SIRT have yet to be clarified but our initial experience suggests that using SIRT in HCC patients after TACE therapy has been exhausted may not be the best approach. <h3>Disclosure of Interest</h3> None Declared
Incidence and Kinetics Of Full Donor Chimerism and The Impact Of Minimal Residual Disease Status Following Outpatient Non-Myeloablative Allogeneic Stem Cell Transplantation For Myeloma
Authors: Philip Campbell, Tongted Das, David Kipp, Patricia A. Walker, Jenny Muirhead, Sharon Avery, Sushrut S. Patil, David J. Curtis, Anthony P. Schwarer, Anna Kalff, Andrew Spencer
Journal: Blood (2013)
G-CSF-induced sympathetic tone provokes fever and primes antimobilizing functions of neutrophils via PGE2
Authors: Yuko Kawano, Chie Fukui, Masakazu Shinohara, Kanako Wakahashi, Shinichi Ishii, Tomohide Suzuki, Mari Sato, Noboru Asada, Hiroki Kawano, Kentaro Minagawa, Akiko Sada, Tomoyuki Furuyashiki, Satoshi Uematsu, Shizuo Akira, Toshimitsu Uede, Shuh Narumiya, Toshimitsu Matsui, Yoshio Katayama
Journal: Blood (2016)
Enzastaurin Treatment Affects Multiple Regulatory Pathways at Transcriptome and Cellular Proteome Level of Mantle Cell Lymphoma
Authors: Marc Weinkauf, Grit Hutter, Yvonne Zimmermann, Malte Rieken, Alessandro Pastore, Elena Hartmann, Andreas Rosenwald, Wolfgang Hiddemann, Martin H. Dreyling
Journal: Blood (2010)
AB1129-HPR Cross-Cultural Adaptation and Validation of The Patient Reported Outcome Measures Questionnaire for Inflammatory Arthritis for Bulgarian-Speaking Individuals
Authors: Y. El Miedany, R. Nestorova, T. Petranova, M. El Gaafary
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The PROMs-Arthritis questionnaire [1] was developed to evaluate the patient reported outcomes in individuals with inflammatory arthritis. Translation of the questionnaire to other languages will provide a standard outcome measure across populations. <h3>Objectives</h3> To translate the English version of the Patient Reported Outcome Measures for inflammatory arthritis (PROMs-Arthritis) to Bulgarian; and evaluate the psychometric properties of the Bulgarian version. <h3>Methods</h3> The PROMs-Arthritis questionnaire was cross-culturally adapted to Bulgarian, according to established guidelines. The validity and reliability of the Bulgarian version were assessed in 110 patients with rheumatoid arthritis (RA) as well as 44 healthy control. The questionnaire includes assessment for functional disability, quality of life, VAS for joint pain, patient global status, fatigue, duration of morning stiffness, assessment of co-morbidities, patient activation as well as self-reported joint pain. <h3>Results</h3> The expert committee and the participants considered the questionnaire to have good face and content validity. Dimensionality analysis revealed a 1-factor solution, explaining 97% of the total variance. Known group validity was demonstrated by significant differences between patients compared with the asymptomatic group (<i>P</i>&lt;0.001). An item analysis showed a high degree of internal consistency (Cronbach α=0.805).The Bulgarian version exhibited excellent test-retest reliability (intraclass correlation coefficient =0.805 for the arthritis group). The questionnaire items correlated significantly (p&lt;0.01) with clinical parameters of disease activity (DAS-28), physician global assessment, ESR and CRP levels. RA patient self-reported tender joints correlated significantly with the physicians9 scores (0.893). Changes in functional disability, quality of life as well as Patient Activation scores showed significant (p&lt;0.01) variation, with diseases activity status (DAS-28). The questionnaire showed also a high degree of comprehensibility (9.4). <h3>Conclusions</h3> Integrating patient reported outcome measures into standard clinical practice is feasible and applicable. The Bulgarian version, adapted from the original English PROMs-Arthritis questionnaire, shows a considerable validity and reliability, and its psychometric properties are comparable with the original version. <h3>References</h3> El Miedany Y et al. Clin Exp Rheumatol. 2010 Sep-Oct;28(5):734–44. <h3>Disclosure of Interest</h3> None declared
Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial
Authors: Hagop M. Kantarjian, Dong-Wook Kim, Javier Pinilla-Ibarz, Philipp le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane Apperley, H. Jean Khoury, Moshe Talpaz, John F. DiPersio, Daniel DeAngelo, Elisabetta Abruzzese, Delphine Rea, Michele Baccarani, Martin C Muller, Carlo Gambacorti-Passerini, Stephane Wong, Stephanie Lustgarten, Victor M. Rivera, Tim Clackson, Christopher D. Turner, Frank G Haluska, Francois Guilhot, Michael W. Deininger, Andreas Hochhaus, Timothy P. Hughes, John Goldman, Neil Shah, Jorge E. Cortes, The PACE Study Group
Journal: Blood (2012)
Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease
Authors: Carolin Lackner, Walter Spindelboeck, Johannes Haybaeck, Philipp Douschan, Florian Rainer, Luigi Terracciano, Josef Haas, Andrea Berghold, Ramon Bataller, Rudolf E. Stauber
Journal: Journal of Hepatology (2016)
Denaturing- HPLC and HR-1 Melter-Based Detection of ABL Mutations in Patients with Chronic Myelogenous Leukemia (CML).
Authors: Il-Kwon Lee, Ju Hyun Yun, Nan Young Kim, Jeong-Hwa Choi, Yeo-Kyeoung Kim, Hee Nam Kim, Kyeong-Soo Park, Je-Jung Lee, Myung Geun Shin, Chan Choi, Hoon Kook, Tai Ju Hwang, Moo Rim Park, Deog Yeon Jo, Jong Ho Won, Hyeoung-Joon Kim
Journal: Blood (2005)
The Challenge of Myeloma-Related Thromboembolic Disease: Can Thrombin Generation Assay May Detect Disease-Related Hypercoagulability?
Authors: Yesim G. Dargaud, Marc Fouassier, Sophie Ducastelle, Philippe Moreau, Charles Dumontet, Mauricette Michallet, Jean-Claude Bordet, Claude Negrier
Journal: Blood (2014)
SP0066 Peripheral Processing and Central Modulation of Pain
Authors: S. Sikandar
Journal: Annals of the Rheumatic Diseases (2016)

The ability to perceive pain from cutaneous to deeper tissues and organs is part of the normal sensory repertoire of many animal species. Nonetheless, ongoing chronic pain substantially reduces the quality of life of suffering patients, often accompanied with co-morbidities that further add to the socioeconomic burden of chronic pain. Pain harnesses many neuronal systems from the periphery along the central neuraxis to higher centres of the brain. Following tissue or nerve injury, sustained activity in peripheral afferents can significantly increase the excitability of spinal cord neurones and higher centres in the brain, producing central sensitisation with ensuing pain and altered sensory function. This talk will outline our current understanding of pain pathways in the peripheral and central nervous system. The significant role of supraspinal influences and changes in spinal excitability in the development and maintenance of abnormal sensitivity in chronic pain states will be discussed. Indeed, descending projections from the brain to the spinal cord can protect again persistent pain, e.g. in placebo analgesia, and central sensitization can occur in the absence of peripheral pathology, e.g. after opioid-induced hyperalgesia. This talk will cover the pro-nociceptive changes that occur in peripheral, spinal and supraspinal centres in chronic pain states and relate this to potential improvement of targeted analgesic therapies. <h3>Disclosure of Interest</h3> None declared
Microbial, metabolomic, and immunologic dynamics in a relapsing genetic mouse model of colitis induced by T-synthase deficiency
Authors: Jonathan P. Jacobs, Lin Lin, Maryam Goudarzi, Paul Ruegger, Dermot P. B. McGovern, Albert J. Fornace, James Borneman, Lijun Xia, Jonathan Braun
Journal: Gut Microbes (2016)

Intestinal dysbiosis is thought to confer susceptibility to inflammatory bowel disease (IBD), but it is unknown whether dynamic changes in the microbiome contribute to fluctuations in disease activity. We explored this question using mice with intestine-specific deletion of C1galt1 (also known as T-synthase) (Tsyn mice). These mice develop spontaneous microbiota-dependent colitis with a remitting/relapsing course due to loss of mucin core-1 derived O-glycans. 16S rRNA sequencing and untargeted metabolomics demonstrated age-specific perturbations in the intestinal microbiome and metabolome of Tsyn mice compare with littermate controls at weeks 3 (disease onset), 5 (during remission), and 9 (after relapse). Colitis remission corresponded to increased levels of FoxP3+RORγt+CD4+ T cells in the colonic lamina propria that were positively correlated with operational taxonomic units (OTUs) in the S24–7 family and negatively correlated with OTUs in the Clostridiales order. Relapse was characterized by marked expansion of FoxP3-RORγt+CD4+ T cells expressing IFNγ and IL17A, which were associated with Clostridiales OTUs distinct from those negatively correlated with FoxP3+RORγt+CD4+ T cells. Our findings suggest that colitis remission and relapse in the Tsyn model may reflect alterations in the microbiome due to reduced core-1 O-glycosylation that shift the balance of regulatory and pro-inflammatory T cell subsets. We investigated whether genetic variation in C1galt1 correlated with the microbiome in a cohort of 78 Crohn's disease patients and 101 healthy controls. Polymorphisms near C1galt1 (rs10486157) and its molecular chaperone, Cosmc (rs4825729), were associated with altered composition of the colonic mucosal microbiota, supporting the relevance of core-1 O-glycosylation to host regulation of the microbiome.
Prognostic Factors Associated with Outcomes of RIC and MAC Hematopoietic Stem Cell Transplantation: An Indication for the Selection of Conditioning
Authors: Tetsuyuki Kiyokawa, Shoichi Nagakura, Michihiro Hidaka, Takahiro Yano, Kazutaka Sunami, Seiichi Okamura, Naokuni Uike, Motohiro Hamaguchi, Takahiro Matsui, Keizo Horibe, Kensaku Sato, Toshiro Kawakita, Fumio Kawano
Journal: Blood (2008)